CDC Group Finds No Evidence to Support Use of LabCorp's ColoSure Test in General Risk Population

Exact Sciences, which licensed the intellectual property behind ColoSure to LabCorp, is developing a next-generation, multi-gene test for colorectal cancer and plans to start clinical trials later this year to support a premarket approval application with the FDA.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.